A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe
A phase 1/2 trial of Lenalidomide, Dexamethasone, Daratumumab in multiple myeloma, run by AbbVie, now recruiting.
Overview
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations is a phase 1/2 interventional study registered as NCT06892522 by AbbVie, with 602 participants planned, started 2025-06-30 and due to reach its primary completion in 2035-12. Interventions recorded: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple
Shares Iberdomide, Carfilzomib, Daratumumab, Dexamethasone.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, Lenalidomide, AbbVie (incl. ImmunoGen, Capstan).
- TrialA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
Shares Mezigdomide, Carfilzomib, Dexamethasone, Multiple myeloma.
- TrialA Study of Daratumumab
Shares Carfilzomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Mezigdomide, Carfilzomib, Daratumumab, Dexamethasone.
- TrialStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Shares Carfilzomib, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Iberdomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.